Squamous Cell Carcinoma | Norton Healthcare

Indication: Squamous Cell Carcinoma

Phase III Study of Buparlisib (AN2025) Plus Paclitaxel Compared to Paclitaxel Alone in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Sub-indication: Head and Neck Cancer

Study Type: Drug Study

Principal Investigator: Jaspreet Grewal, M.D.
Norton Cancer Institute

Sponsor: Sponsor: Adlai Nortye USA Inc

Learn more at ClinicalTrials.gov

Email for more information: Head&Neck-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.